Kimberly N. Smitheman

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat et al. · Cancer Cell · 2015 · 498 citations · Full text

Oncogenic Agent, Medicine, Epigenetic Change +9

Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)

Michael T. McCabe, Alan P. Graves, Gopinath Ganji et al. · Proceedings of the National Academy of Sciences · 2012 · 481 citations · Full text

Histone Modifications, Epigenetic Change, Pathology +20

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by <i>NRAS</i> or <i>MEK</i> Mutations

James Greger, Stephen D. Eastman, Vivian Zhang et al. · Molecular Cancer Therapeutics · 2012 · 353 citations

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

Tara Rheault, John Stellwagen, George M. Adjabeng et al. · ACS Medicinal Chemistry Letters · 2013 · 253 citations · Full text

B-raf-driven Tumors, Antitumor Activity, Hyperactive Signaling +16

Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions

Alastair J. King, Marc R. Arnone, Maureen R. Bleam et al. · PLoS ONE · 2013 · 212 citations · Full text

Dermatology, Tumor Biology, Signaling Pathway +17